Related Experiment Video

Updated: May 25, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Minocycline inhibits growth of epithelial ovarian cancer

Mohammad H Pourgholami1, Ahmed H Mekkawy, Samina Badar

  • 1Cancer Research Laboratories, Department of Surgery, St. George Hospital, University of New South Wales, Sydney, NSW 2217, Australia. mh.pourgholami@unsw.edu.au

Gynecologic Oncology
|January 19, 2012
PubMed
Abstract

Insights

Minocycline effectively inhibits ovarian cancer cell growth and tumor development by halting cell division and promoting cell death. These findings support further research into minocycline as a potential ovarian cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Ovarian cancer remains a leading cause of cancer-related deaths in women.
  • Novel therapeutic strategies are urgently needed to improve patient outcomes.

Purpose of the Study:

  • To investigate the anti-cancer effects of minocycline on ovarian cancer cells.
  • To elucidate the molecular mechanisms underlying minocycline's action.
  • To evaluate minocycline's efficacy in inhibiting ovarian tumor growth in vivo.

Main Methods:

  • Human ovarian cancer cell lines (OVCAR-3, SKOV-3, A2780) were used to assess minocycline's impact on proliferation, cell cycle, and apoptosis.
  • OVCAR-3 xenografts in nude mice were utilized to examine minocycline's in vivo anti-tumor effects.

Main Results:

  • Minocycline significantly inhibited ovarian cancer cell proliferation and colony formation.
  • It induced cell cycle arrest at the G(0) phase by down-regulating cyclins A, B, and E, suppressing DNA synthesis.
  • Minocycline triggered apoptosis, evidenced by DNA laddering, caspase-3 activation, and PARP-1 cleavage.
  • In vivo, minocycline suppressed tumor proliferation, angiogenesis, and overall tumor growth in mice.

Conclusions:

  • Minocycline demonstrates potent anti-cancer properties against ovarian cancer in vitro and in vivo.
  • The drug affects key cell cycle regulators and induces apoptosis.
  • These results provide a foundation for exploring minocycline as a therapeutic agent for ovarian cancer.

More Related Videos

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum05:42

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum

Published on: January 26, 2024

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.